NASDAQ:SLDB
Solid Biosciences Inc. Stock News
$10.39
+0.0500 (+0.484%)
At Close: May 10, 2024
Implied Volatility Surging for Solid Biosciences (SLDB) Stock Options
09:06am, Wednesday, 17'th Mar 2021
Investors need to pay close attention to Solid Biosciences (SLDB) stock based on the movements in the options market lately.
Solid Biosciences (SLDB) Announces DMD Study Data, Stock Down
12:07pm, Tuesday, 16'th Mar 2021
Solid Biosciences' (SLDB) lead gene therapy candidate achieves positive improvements in DMD patients. However, it fails to cheer investors.
Why Solid Biosciences Stock Is Crashing Today
11:44am, Tuesday, 16'th Mar 2021
Investors appear to be skeptical about the biotech's latest clinical update.
Solid Bio's DMD Gene Therapy Shows Promising Early Data, No New Safety Concerns, But Fails To Cheer Investors
07:57am, Tuesday, 16'th Mar 2021
Solid Biosciences Inc (NASDAQ: SLDB) reported interim functional, biomarker data, and patient-reported outcome measures from its ongoing IGNITE Phase 1/2 trial of its lead gene therapy candidate,
- Interim data from six patients provide evidence of a potential benefit of SGT-001 in functional endpoints of North Star Ambulatory Assessments (NSAA), 6-minute walk test (6MWT), pulmonary function t
Solid Biosciences Reports Inducement Grant to New Chief Legal Officer
07:35am, Thursday, 04'th Mar 2021
CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne)
- IGNITE DMD Principal Investigator, Dr. Barry Byrne, to present efficacy and safety data from the ongoing IGNITE DMD trial on Thursday, March 18-
Solid Biosciences to Present at Upcoming Investor Conferences
07:30am, Wednesday, 17'th Feb 2021
CAMBRIDGE, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne),
Why Solid Biosciences Stock Is Sinking Today
11:57am, Friday, 08'th Jan 2021
Blame it on Sarepta.
Solid Biosciences to Present at 39th Annual J.P. Morgan Healthcare Conference
07:30am, Wednesday, 06'th Jan 2021
CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne),
Why 3 Health Care Stocks Are Moving: Tv Therapeutics, Solid Biosciences, Sellas Life Sciences
12:33pm, Friday, 11'th Dec 2020
Tv Therapeutics (NASDAQ: VTVT) shares were trading higher on Friday after the company said its Phase 2 Simplici-T1 study of TTP399 achieved the primary objective of a statistically significant reduc
Solid Biosciences Announces $90 Million Private Placement
07:30am, Friday, 11'th Dec 2020
CAMBRIDGE, Mass., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne),
Solid Biosciences: Does Not Look Like A Solid Investment Given Its Unsatisfactory Trial Data
08:41am, Tuesday, 10'th Nov 2020
SLDB is recovering from clinical holds placed on lead drug candidate SGT-001 for DMD. They entered a new deal with Ultragenyx, and have cash for the next year.
Solid Biosciences' (SLDB) CEO Ilan Ganot on Q3 2020 Results - Earnings Call Transcript
02:16am, Sunday, 08'th Nov 2020
Solid Biosciences' (SLDB) CEO Ilan Ganot on Q3 2020 Results - Earnings Call Transcript
Solid Biosciences Reports Third Quarter 2020 Financial Results and Provides Business Update
07:00am, Thursday, 05'th Nov 2020
–IGNITE DMD clinical trial expected to resume dosing in the first quarter of 2021 –
